Jerry SH Lee, PhD

Associate Professor of Clinical Medicine and Chemical Engineering and Material Sciences

Chief Science and Innovation Officer of the Lawrence J. Ellison Institute for Transformative Medicine

Image of Jerry SH Lee, PhD
Is this your profile? Click to edit

Overview

Dr. Lee is an Associate Professor of Clinical Medicine, Chemical Engineering and Material Sciences, and Quantitative and Computational Biology at the University of Southern California Keck School of Medicine, Viterbi School of Engineering, and Dornsife College of Letters, Arts, and Sciences. He also serves as the Chief Science and Innovation Officer for the Ellison Medical Institute and provides leadership, guidance, vision, and development of research capabilities for executing the Institute’s research projects and will be responsible for planning, implementing, and evaluating scientific direction, projects, and funding to sustain high-impact programs in support of a bold vision to transform cancer research in the 21st century.

Prior to joining USC, Dr. Lee served for more than a decade as a Health Sciences Director within the National Cancer Institute’s Office of the Director. Through direct support and use of public-public/public-private partnerships, he deployed programs focused on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit.

In 2016, Dr. Lee was assigned to Office of the Vice President to serve as the Deputy Director for Cancer Research and Technology for the White House Cancer Moonshot Task Force. A few key efforts he helped coordinate include the Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network, international collaborations to share molecular characterization datasets, the Blood Profiling Atlas in Cancer pilot, as well as co-chairing an interagency group focused on cancer data and technology policy issues.

Dr. Lee’s research involves elucidating the interplay between biophysical and biochemical drivers of age-related diseases and has co-authored over fifty papers, five book chapters, and one book. He is a member of the Department of Veterans Affairs’ National Research Advisory Council, the National Academies Board on Science, Technology, and Economic Policy’s Innovation Policy Forum, and the Health and Environmental Sciences Institute’s Board of Trustees. Dr. Lee earned his B.S. degree in biomedical engineering and Ph.D. in chemical and biomolecular engineering from Johns Hopkins University.

Awards

  • National Cancer Institute: Director’s Merit Award, 2014
     – 2017
  • National Cancer Institute: Director’s Merit Award, 2010
     – 2012
  • NASA: NASA Graduate Student Research Fellowship Award, 2004
     – 2006
  • Tau Beta Pi, 2004

Education and Training

  • Johns Hopkins University, Baltimore, MD — PhD — 2006 — Chemical and Biomolecular Engineering
  • Johns Hopkins University, Baltimore, MD — BS — 2001 — Biomedical Engineering

Research Keywords

  • Cell and tissue biophysics
  • Cell migration and motility
  • Data-driven molecular medicine
  • Adaptive learning healthcare system

Publications

  • Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure. Front Artif Intell. 2026; 9:1796682.. View in PubMed
  • Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0. JCO Precis Oncol. 2026 May; 10(5):e2501243.. View in PubMed
  • Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer’s Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation. JCO Precis Oncol. 2026 Jan; 10:e2500267.. View in PubMed
  • Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types. Discov Oncol. 2025 Dec 03; 17(1):36.. View in PubMed
  • Drowning in data, starving for access: unlocking the bottleneck in molecular medicine and cancer research. Health Syst (Basingstoke). 2026; 15(1):1-5.. View in PubMed
  • Proteogenomic characterization of invasive breast tumors in young women. NPJ Breast Cancer. 2025 Aug 18; 11(1):94.. View in PubMed
  • Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection. Clin Cancer Res. 2025 Jun 13; 31(12):2267-2270.. View in PubMed
  • Monitoring the rate and variability of somatic genomic alterations using long-read sequencing. Sci Rep. 2025 Jun 11; 15(1):18397.. View in PubMed
  • Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons. Clin Transl Sci. 2025 04; 18(4):e70227.. View in PubMed
  • Lexicon for blood-based early detection and screening: BLOODPAC consensus document. Clin Transl Sci. 2024 09; 17(9):e70016.. View in PubMed